Unlocking the promise of oncolytic virotherapy in glioma: Combination with chemotherapy to enhance efficacy

Drew A. Spencer; Jacob S. Young; Deepak Kanojia; Julius W. Kim; Sean P. Polster; Jason P. Murphy; Maciej S. Lesniak

doi:10.4155/tde.14.123

Unlocking the promise of oncolytic virotherapy in glioma: Combination with chemotherapy to enhance efficacy

Drew A. Spencer, Jacob S. Young, Deepak Kanojia, Julius W. Kim, Sean P. Polster, Jason P. Murphy, Maciej S. Lesniak^*

^*Corresponding author for this work

Neurological Surgery

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

Malignant glioma is a relentless burden to both patients and clinicians, and calls for innovation to overcome the limitations in current management. Glioma therapy using viruses has been investigated to accentuate the nature of a virus, killing a host tumor cell during its replication. As virus mediated approaches progress with promising therapeutic advantages, combination therapy with chemotherapy and oncolytic viruses has emerged as a more synergistic and possibly efficacious therapy. Here, we will review malignant glioma as well as prior experience with oncolytic viruses, chemotherapy and combination of the two, examining how the combination can be optimized in the future.

Original language	English (US)
Pages (from-to)	453-468
Number of pages	16
Journal	Therapeutic Delivery
Volume	6
Issue number	4
DOIs	https://doi.org/10.4155/tde.14.123
State	Published - Apr 1 2015

Funding

ASJC Scopus subject areas

Pharmaceutical Science

Access to Document

10.4155/tde.14.123

Cite this

@article{89bd0f62ef1547ff814878a16b6ef7ee,

title = "Unlocking the promise of oncolytic virotherapy in glioma: Combination with chemotherapy to enhance efficacy",

abstract = "Malignant glioma is a relentless burden to both patients and clinicians, and calls for innovation to overcome the limitations in current management. Glioma therapy using viruses has been investigated to accentuate the nature of a virus, killing a host tumor cell during its replication. As virus mediated approaches progress with promising therapeutic advantages, combination therapy with chemotherapy and oncolytic viruses has emerged as a more synergistic and possibly efficacious therapy. Here, we will review malignant glioma as well as prior experience with oncolytic viruses, chemotherapy and combination of the two, examining how the combination can be optimized in the future.",

author = "Spencer, {Drew A.} and Young, {Jacob S.} and Deepak Kanojia and Kim, {Julius W.} and Polster, {Sean P.} and Murphy, {Jason P.} and Lesniak, {Maciej S.}",

note = "Publisher Copyright: {\textcopyright} 2015 Future Science Ltd.",

year = "2015",

month = apr,

day = "1",

doi = "10.4155/tde.14.123",

language = "English (US)",

volume = "6",

pages = "453--468",

journal = "Therapeutic Delivery",

issn = "2041-5990",

publisher = "Future Science",

number = "4",

}

TY - JOUR

T1 - Unlocking the promise of oncolytic virotherapy in glioma

T2 - Combination with chemotherapy to enhance efficacy

AU - Spencer, Drew A.

AU - Young, Jacob S.

AU - Kanojia, Deepak

AU - Kim, Julius W.

AU - Polster, Sean P.

AU - Murphy, Jason P.

AU - Lesniak, Maciej S.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Malignant glioma is a relentless burden to both patients and clinicians, and calls for innovation to overcome the limitations in current management. Glioma therapy using viruses has been investigated to accentuate the nature of a virus, killing a host tumor cell during its replication. As virus mediated approaches progress with promising therapeutic advantages, combination therapy with chemotherapy and oncolytic viruses has emerged as a more synergistic and possibly efficacious therapy. Here, we will review malignant glioma as well as prior experience with oncolytic viruses, chemotherapy and combination of the two, examining how the combination can be optimized in the future.

AB - Malignant glioma is a relentless burden to both patients and clinicians, and calls for innovation to overcome the limitations in current management. Glioma therapy using viruses has been investigated to accentuate the nature of a virus, killing a host tumor cell during its replication. As virus mediated approaches progress with promising therapeutic advantages, combination therapy with chemotherapy and oncolytic viruses has emerged as a more synergistic and possibly efficacious therapy. Here, we will review malignant glioma as well as prior experience with oncolytic viruses, chemotherapy and combination of the two, examining how the combination can be optimized in the future.

UR - http://www.scopus.com/inward/record.url?scp=84929753792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929753792&partnerID=8YFLogxK

U2 - 10.4155/tde.14.123

DO - 10.4155/tde.14.123

M3 - Review article

C2 - 25996044

AN - SCOPUS:84929753792

SN - 2041-5990

VL - 6

SP - 453

EP - 468

JO - Therapeutic Delivery

JF - Therapeutic Delivery

IS - 4

ER -

Unlocking the promise of oncolytic virotherapy in glioma: Combination with chemotherapy to enhance efficacy

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this